Form 8-K - Current report:
SEC Accession No. 0001628280-25-016824
Filing Date
2025-04-04
Accepted
2025-04-04 16:54:52
Documents
14
Period of Report
2025-04-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lenz-20250404.htm   iXBRL 8-K 30552
2 EX-1.1 exhibit11-8xkshelf.htm EX-1.1 296112
  Complete submission text file 0001628280-25-016824.txt   513869

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lenz-20250404.xsd EX-101.SCH 1770
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lenz-20250404_lab.xml EX-101.LAB 23433
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lenz-20250404_pre.xml EX-101.PRE 13570
17 EXTRACTED XBRL INSTANCE DOCUMENT lenz-20250404_htm.xml XML 3138
Mailing Address 201 LOMAS SANTA FE DRIVE, SUITE 300 SOLANA BEACH CA 92075
Business Address 201 LOMAS SANTA FE DRIVE, SUITE 300 SOLANA BEACH CA 92075 858-925-7000
LENZ Therapeutics, Inc. (Filer) CIK: 0001815776 (see all company filings)

EIN.: 844867570 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40532 | Film No.: 25815572
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)